NEW YORK, Nov. 28, 2023 /PRNewswire/ — The open-angle glaucoma therapeutics market is expected to grow by USD 2.36 billion from 2022 to 2027. In addition, the momentum of the market will progress at a CAGR of 6.4% during the forecast period, according to Technavio Research. The market is segmented by channel (hospital pharmacy, retail pharmacy, and online pharmacy), product (PGAS and non-PGAS), and geography (North America, Europe, Asia, and the Rest of the World (ROW)). North America is estimated to contribute 51% to the growth of the global market during the forecast period. The high prevalence of glaucoma is primarily a factor that contributes to market growth in the region. Public organizations and service providers in this area have also increased their awareness of these illnesses through various educational programs, because of the large number of people affected by eye disorders. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read a PDF Sample Report
Technavio has announced its latest market research report titled Global Open-Angle Glaucoma Therapeutics Market 2023-2027
Company Profile:
AbbVie Inc., Alcon Inc., Bausch Health Companies Inc., D.Western Therapeutics Institute Inc., Hikma Pharmaceuticals Plc, Inotek Pharmaceuticals, Merck and Co. Inc., Nicox S.A., Novartis AG, Ocuphire Pharma Inc, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Santen Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
AbbVie Inc.- The company offers open-angle glaucoma therapeutics such as Lumigan and Combigan.
To gain access to more company profiles available with Technavio, buy the report!
Open-Angle Glaucoma Therapeutics Market: Segmentation Analysis
The market share growth by the hospital pharmacy segment will be significant during the forecast period. Hospital pharmacies play a crucial role in distributing medicine and are often one of the main sources of medicinal products used to treat glaucoma within hospital settings.
Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a PDF Sample Report
“Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021”- Technavio
Open-Angle Glaucoma Therapeutics Market: Driver & Trend:
Promising pipeline and recent approvals
Increasing demand for combination drugs
Rising geriatric population
The promising pipeline and recent approvals are key factors driving market growth. Substantial investments are being made in developing new medicines for Open-angle glaucoma by pharmaceutical companies due to the large incidence of this disease. Additionally, a number of companies have received approval to market their medicines for the treatment of open-angle glaucoma in recent weeks.
The growing awareness about glaucoma is a major trend in an open-angle glaucoma therapeutics market.
Identify key trends, drivers, and challenges in the market. Download a sample report to gain access to this information.
Related Reports:
The immunoassay market size is estimated to grow by USD 8.64 billion at a CAGR of 4.42% between 2023 and 2028.
The amyotrophic lateral sclerosis (ALS) treatment market size is estimated to grow by USD 663.7 million at a CAGR of 12.79% between 2023 and 2028.
What are the key data covered in this open-angle glaucoma therapeutics market report?
CAGR of the market during the forecast period
Detailed information on factors that will drive the growth of the open-angle glaucoma therapeutics market between 2022 and 2027
Precise estimation of the open-angle glaucoma therapeutics market size and its contribution to the market in focus on the parent market
Accurate predictions about upcoming trends and changes in consumer behavior
Growth of the open-angle glaucoma therapeutics market across North America, Europe, Asia, and ROW
A thorough analysis of the market’s competitive landscape and detailed information about companies
Comprehensive analysis of factors that will challenge the growth of open-angle glaucoma therapeutics market companies
ToC:
Executive Summary
Market Landscape
Market Sizing
Historic Market Sizes
Five Forces Analysis
Market Segmentation by Channel
Market Segmentation by Product
Market Segmentation by Geography
Customer Landscape
Geographic Landscape
Drivers, Challenges, & Trends
Company Landscape
Company Analysis
Appendix
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base comprises enterprises of all sizes, including over 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com
SOURCE Technavio
